key: cord-1012132-t7s5213w
authors: Guisado Hernández, Paloma; Blanco Lobo, Pilar; Villaoslada, Isabel; de Felipe, Beatriz; Lucena, José M.; Martín Gutierrez, Guillermo; Castro, María José; Gutiérrez Valencia, Alicia; Sánchez Codez, María Isabel; Gaboli, Mirella; Neth, Olaf; Olbrich, Peter
title: SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?
date: 2021-06-09
journal: J Clin Immunol
DOI: 10.1007/s10875-021-01081-9
sha: 5e6e305bba38851a6ee77ef0551b3dd5ab228636
doc_id: 1012132
cord_uid: t7s5213w

nan

To the Editor, Recently, 94 inborn errors of immunity (IEI) patients suffering from COVID-19 have been described, overall demonstrating a mild phenotype [1] although more severe disease manifestations have been suggested for patients with alterations in the interferon (IFN) signaling pathway, including auto-antibodies against type I IFN [2] . Patients with STAT1 GOF mutations show a complex and often severe phenotype, combining an increased susceptibility of fungal, (myco-) bacterial and viral infections as well as autoimmune and autoinflammatory manifestations [3] . Characteristically, in response to type I and type II IFN stimulation, these patients show STAT1 hyperphosphorylation [3, 4] . Whether in the context of SARS-CoV-2 infection, the hyperactivation of the IFN-JAK1/2-STAT1 pathway would be protective (antiviral effect) or deleterious (hyperinflammation) is unclear. Ruxolitinib (a selective JAK1/2 inhibitor) has been successfully used in STAT1 GOF patients controlling many disease manifestations [5] and also resulted in improved pulmonary function and faster recovery from lymphopenia in previously healthy individuals suffering from severe COVID-19 [6] .

We provide clinical and laboratory data of a STAT1 GOF adolescent suffering from mild and overall uncomplicated SARS-CoV-2 while receiving ruxolitinib treatment.

An 11-year-old girl presented in early childhood with recurrent respiratory tract infections, aphthous stomatitis, oral thrush, enteropathy, and subarachnoideal hemorrhage after rupture of a cerebral aneurysm ( Supplementary Fig. 1 ). She was diagnosed with a previously described de novo STAT1 GOF mutation (c.1053G > T/p.Leu351Phe); initial management was supportive, consisting in antibiotic and antifungal prophylaxis. Ruxolitinib therapy was initiated in March 2018 at 0.2 mg/kg/day and progressively increased to 0.5 mg/kg/ day achieving appropriate disease control. Under therapy, total STAT1 expression remained elevated, while STAT1 hyperphosphorylation and previously increased STAT1 downstream targets such as CXCL10 and PD-L1 were controlled ( Fig. 1A by qPCR, her father being the index case. She developed only mild productive cough, low-grade fever, myalgia, and fatigue. After discussion with the family and medical team, it was decided to maintain ruxolitinib therapy. Due to fever persistence, she was admitted for observation, and empiric oral antibiotic therapy (amoxicillin-clavulanic acid) was prescribed for 7 days, while blood and sputum cultures were negative and a 20 target FILMARRAY™ Respiratory Panel (Biomerieux) confirmed SARS-CoV-2 infection only. Fever vanished at day + 3 when she was discharged home. She maintained good clinical health in her follow-up visits at weeks 3 and 5; however, she developed candida vulvovaginitis at week 6.

There was overall lymphopenia with normal T and B cell distribution at week 1, which subsequently recovered (Supplementary Table 1 ). Ferritin and platelets were normal and C-reactive protein (CRP) only mildly raised at week 1, suggesting no evidence of hyperinflammation.

Consecutive molecular and serology results are summarized in Fig. 1D . While SARS-CoV-2 qPCRs were strongly positive in weeks 1 and 3 and weakly positive at week 5 and 6 of infection, SARS-CoV-2 IgM and IgG were detected at weeks 3 and 5, the latter persisting at week 6.

Using whole blood without stimulation, total STAT1 levels in CD8 + T cells from the patient before and during infection were measured using flow cytometry and compared with a healthy control (HC) (Fig. 1A) . STAT1 levels were overall higher in the patient compared to the HC; this was less evident in the first week of infection. Phosphorylated STAT1 (pSTAT1) levels after IFNα stimulation were lower in patient's cells than in HC during the complete follow-up, suggesting a good immunological control under ruxolitinib treatment ( Fig. 1B; Supplementary  Fig. 2A and 3 ). An increment in pSTAT1 upon IFNα stimulation was observed at week 1, but not before infection. In addition, stimulation of patient's CD14 + monocytes with IFNγ showed pSTAT1 phosphorylation similar to the HC ( Supplementary Fig. 2B ) further suggesting an immunomodulatory effect of ruxolitinib, without complete abolishment of the IFN-JAK-STAT axis.

In order to assess the potential effect of infection on IFN response, the transcription levels of STAT1 and STAT1 downstream genes (CXCL10 and PD-L1) were evaluated in PBMCs before and after IFNα stimulation (Fig. 1C) . While the expression of these genes pre-infection was low and similar to HC, gene expression after IFNα stimulation was overall raised during infection, being highest at week 1 and subsequently decreasing.

Furthermore, secretion of CXCL10 protein in supernatant from PBMCs, before and after IFNα stimulation, was evaluated confirming CXCL10 upregulation found in the transcription assay (Supplementary Fig. 4) .

IL6, IFNγ, and CXCL10 serum levels were measured as indicators of inflammatory responses during SARS-CoV-2 infection (Fig. 1E) . The levels of these molecules were markedly elevated at week 1, and despite an overall decrease at week 3, only IL6 reached normal levels. Six weeks after infection, CXCL10 and IFNγ levels continued to be raised and IL6 increased again, possibly due to an intercurrent vaginal candida infection.

For laboratory details, please refer to Supplementary Methods.

We present, the first case of an adolescent with STAT1 GOF mutation under ruxolitinib therapy who suffered from prolonged but surprisingly mild SARS-CoV-2 infection, suggesting JAK-inhibition in this clinical setting not to be harmful. This is an important observation keeping in mind that infectious complications (fungal and herpesvirus) under JAK inhibition in STAT1 GOF patients have been described [7] . Previously, only one STAT1 GOF patient with COVID-19 was reported. In that case, SARS-CoV-2 infection was asymptomatic and the patient remained on immunoglobulin substitution only [1] . At the time of hospital admission, our patient has been receiving ruxolitinib treatment for 3 years, being associated with clinical improvement of STAT1 GOF-associated symptoms without any adverse events. Despite lack of evidence for the effect of JAK inhibition on clinical outcomes of SARS-CoV-2 infection, ruxolitinib treatment was maintained during infection monitoring the activity of JAK/STAT1 pathway by flow cytometry and mRNA transcription levels.

Although increased total STAT1 levels were documented, hyperphosphorylation of STAT1 was not observed during the complete follow-up, proposing ruxolitinib to be effective in controlling cytokine hyperresponsiveness typically found in STAT1 GOF patients, even in the context of SARS-CoV-2 infection.

Despite ruxolitinib treatment, STAT1-dependent gene transcription during infection was markedly higher in the patient compared to the HC, suggesting an ability to respond to type I interferons, known to play an important role in antiviral immunity as recently described in SARS-CoV-2 infections [2] . No age-matched HC with SARS-CoV-2 infection were available for the experiments, thereby potentially limiting the data interpretation. In addition, serum levels of IL6, IFNγ, and CXCL10 were elevated during infection, supporting the ability of the patient to develop an inflammatory response even under ruxolitinib therapy.

Interestingly, despite receiving immunoglobulin substitution, our patient efficiently mounted IgM and IgG responses to SARS-CoV-2. SARS-CoV-2 qPCR results continued to be positive up to 6 weeks, suggesting persistent infection as reported previously [8] ; although in our case, infectivity was not formally assessed.

In summary, the maintenance of ruxolitinib treatment in this STAT1 GOF patient with SARS-CoV-2 infection was safe and resulted in a balanced residual type I interferon response sufficient to control viral infection whilst avoiding an uncontrolled inflammatory response. Recently, using human lung epithelial cell lines, ruxolitinib therapy was shown to normalize interferon signature genes, induced by SARS-CoV-2 infection, without affecting NF-κB-regulated genes, further supporting our observation [9] . In addition, case reports on its beneficial effect have been described in patients with myelofibrosis and rheumatoid diseases and a recent trial evaluating baricitinib and remdesivir in COVID-19 pneumonia showed promising results [10] [11] [12] . Whether JAK inhibition indeed plays a role in the management of SARS-CoV-2 infections in patients with immune dysregulation syndromes as well as previously healthy subjects remains to be established by collecting prospective data from registries.

The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s10875-021-01081-9.

Author Contribution PGH performed the experiments and wrote the paper. PBL performed the experiments and wrote the paper. IVC performed the experiments and designed the figures. BF performed experiments and reviewed the paper. JML performed the immunophenotyping and reviewed the paper. GM performed microbiologic studies and reviewed the paper. MJC overviewed the flow cytometry experiments and reviewed the paper. AGV performed experiments and reviewed the paper. MISC, medical doctor of the patient, reviewed the paper. MG, medical doctor of the patient, reviewed the paper. ON, medical doctor of the patient, designed the research study and wrote the paper. PO, medical doctor of the patient, designed the research study and wrote the paper.

Coronavirus disease 2019 in patients with inborn errors of immunity: an international study

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype

STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis

Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial

Risks of ruxolitinib in STAT1 gain-of-function-associated severe fungal disease

Shedding of Viable SARS-CoV-2 after immunosuppressive therapy for cancer

SARS-CoV-2 drives JAK1 2 dependent local complement hyperactivation

Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis

SARS CoV-2 infection among patients using immunomodulatory therapies

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations